Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Phathom Pharmaceuticals Inc (NQ: PHAT )

9.340 -0.110 (-1.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
NASDAQ:PHAT Investor Notice: Investigation over Possible Wrongdoing at Phathom Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 09/28/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Phathom Pharmaceuticals, Inc. 
Via SBWire
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/17/2022 -- Phathom Pharmaceuticals, Inc is under investigation over potential securities laws violations connection with certain financial statements. 
Via SBWire
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – PHAT
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Dow Drops More Than 200 Points; Caterpillar Shares Fall Following Q2 Results
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones tumbling more than 200 points on Tuesday. 
Via Benzinga
Nasdaq Turns Positive; Crude Oil Moves Higher
U.S. stocks pared losses midway through trading, with the S&P 500 and Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
Why Applied DNA Sciences Is Trading Higher By 166%, Here Are 75 Stocks Moving In Tuesday's Mid-Day Session
Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD Digital. 
Via Benzinga
Recap: Phathom Pharmaceuticals Q2 Earnings
  Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
FDA Accepts Review Of Phathom Pharmaceuticals' NDA For Vonoprazan
The Food and Drug Administration (FDA) has accepted for review Phathom Pharmaceuticals’ (NASDAQ: PHAT) New Drug Application (NDA) of its lead drug candidate Vonoprazan for the healing of all grades of... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.